V-GLUTATION PLUS

Glutathione (GSH) is the body's most abundant endogenous antioxidant, present in virtually every cell and playing a central role in neutralizing reactive oxygen species (ROS), supporting phase II hepatic detoxification, and maintaining immune homeostasis. Oral supplementation with reduced glutathione has been a subject of debate historically due to concerns over gastrointestinal degradation, but a landmark randomized, double-blind, placebo-controlled trial published in 2015 demonstrated that 500mg/day of oral GSH over 6 months significantly increased red blood cell glutathione levels by up to 30-€“35% compared to baseline, with whole blood GSH rising by approximately 17% (PMID: 26370552). This was accompanied by measurable reductions in oxidative stress biomarkers, including a statistically significant decrease in the oxidized-to-reduced glutathione ratio (GSSG:GSH), confirming that orally supplemented reduced glutathione is bioavailable and biologically active at this dose.

Vitamin C at doses of 250mg has been extensively studied for its role as a water-soluble antioxidant that directly recycles oxidized glutathione (GSSG) back to its active reduced form (GSH), effectively amplifying the antioxidant capacity of supplemented glutathione. A well-cited study by Johnston et al. (1993) demonstrated that Vitamin C supplementation significantly attenuated the depletion of erythrocyte glutathione under conditions of oxidative stress, highlighting its sparing and regenerative relationship with GSH (PMID: 8490668). Additional research has shown that 250mg of Vitamin C -€” a dose above the daily RDA of 90mg for men and 75mg for women -€” achieves near-complete plasma saturation in most healthy adults, meaning the full recycling effect on glutathione can be reliably expected at the dose provided in V-GLUTATION PLUS.

Alpha Lipoic Acid (ALA) at 100mg provides an additional and mechanistically distinct recycling pathway for glutathione. ALA is unique in that it functions as both a water-soluble and fat-soluble antioxidant, and its reduced form, dihydrolipoic acid (DHLA), is a potent electron donor capable of regenerating Vitamin C, Vitamin E, and glutathione simultaneously. A clinical study by Marangon et al. (1999) found that oral ALA supplementation significantly increased plasma glutathione concentrations and reduced lipid peroxidation markers in healthy volunteers, with effects observed within 4 weeks at doses as low as 100-€“300mg/day (PMID: 10063298). Furthermore, ALA activates the Nrf2 transcription factor, which upregulates endogenous glutathione synthesis via increased expression of glutamate-cysteine ligase (GCL), the rate-limiting enzyme in the GSH biosynthesis pathway, providing both immediate antioxidant effects and long-term support for the body's own glutathione production.

The safety profile of all three ingredients in V-GLUTATION PLUS is well-established across numerous clinical trials. The previously cited 6-month RCT on 500mg oral GSH reported no serious adverse events and no clinically significant changes in blood chemistry, liver enzymes, or kidney function markers (PMID: 26370552). Vitamin C at 250mg is substantially below the established tolerable upper intake level (UL) of 2,000mg/day set by the Institute of Medicine, and ALA at 100mg is well within the dosing range used in clinical trials for diabetic neuropathy, where doses up to 600-€“1800mg/day have been used safely for extended periods (PMID: 11319996). Collectively, this formulation presents a favorable risk-to-benefit ratio with strong tolerability data supporting its use across a broad adult population.